Your browser version may not work well with NCBI's Web applications. More information here...
1: Ter Arkh. 1988;60(4):77-80.Links

[Effectiveness and safety of using cyclosporin A in the treatment of primary Sjögren's syndrome]

[Article in Russian]

Drosos AA, Moutsopoulos NM.

We used oral cyclosporine-A (CyA) (5 mg/kg/day) initially in a double blind study for 6 mos. 10 patients received CyA and 10 placebo. At the end of this study it was observed that CyA improved subjective xerostomia, while subjective xerophthalmia, parotid gland enlargement, Schirmer-I-test and parotid flow rate did not show any significant differences in the two study groups. 9 of 10 patients who had received CyA for 6 mos and 9 of 10 in the placebo group continued in an open trial (CyA at the same dose) for an additional 6 mos. At the end of the study the only efficacy of CyA observed was improvement of subjective xerostomia. The side-effects observed were hypertrichosis (14 persons), mild hypertension (4), infections (5) and 3 dropped out because of nausea, tremor, paresthesias and infections. In conclusion, small doses of CyA for 12 mos are rather ineffective for Sjogren's syndrome.

PMID: 3293257 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Cyclosporine (Neoral® , Sandimmune® , Gengraf® )

    Cyclosporine and cyclosporine (modified) are used with other medications to prevent transplant rejection (attack of the transplanted organ by the immune system of the person who received the organ) in people who have rec...

  • Source: AHFS Consumer Medication Information